微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 21.58% | 4.49% | -3.57% | 134/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 22.38% | 15.14% | 4.02% | 133/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 21.51% | 11.08% | 3.12% | 136/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 20.86% | 13.02% | 1.01% | 135/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 20.65% | 5.53% | 6.26% | 131/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 19.43% | -4.49% | 0.36% | 137/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 19.36% | -10.57% | 4.92% | 131/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 18.46% | -7.51% | -5.68% | 141/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 19.57% | -8.34% | -3.82% | 137/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 20.35% | -6.12% | -6.03% | 138/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 21.65% | 2.81% | 8.51% | 133/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 19.96% | 0.92% | -6.53% | 139/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 21.35% | 0.82% | -1.5% | 135/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 21.68% | 0.97% | 2.91% | 134/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 21.06% | -6.41% | 6.52% | 129/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 19.77% | -11.85% | -6.63% | 141/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 21.18% | -8.08% | -1.35% | 132/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 21.47% | -7.64% | -4.61% | 137/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 22.5% | 1.41% | 0.32% | 128/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 22.43% | 0.05% | -2.64% | 139/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 23.04% | 3.95% | -0.88% | 124/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 23.24% | 17.14% | 4.74% | 130/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 22.19% | 33.16% | -1.03% | 117/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 22.42% | -4.98% | 1.17% | 134/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 22.16% | -14.53% | 11.69% | 108/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 19.84% | -21.41% | 19.07% | 123/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 16.66% | -26.56% | -29.38% | 106/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 23.6% | -1.75% | -8.99% | 125/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 25.93% | 4.18% | 2.69% | 97/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 25.25% | -0.96% | 11.27% | 104/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 22.69% | -10.26% | -5.52% | 96/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 24.02% | 8.35% | -3.5% | 122/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 24.89% | 17.91% | -2.37% | 95/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 25.49% | 19.9% | 0.81% | 99/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 25.29% | 28.05% | 14.08% | 94/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 22.17% | 8.12% | 5.02% | 114/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 21.11% | -0.45% | -0.72% | 91/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 21.26% | -2.38% | 7.66% | 96/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 19.75% | -5.69% | -3.68% | 84/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 20.5% | -6.66% | -3.3% | 105/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 21.2% | -10.29% | -2.65% | 76/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 21.78% | -11.46% | 4.02% | 83/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 20.94% | -9.49% | -4.67% | 71/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |